Clinical trial
Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease
NCT00141960 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00141960 |
|---|---|
| Title | Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease |
| Official title | YM1170 Phase 2/3 Study: A Double Blind, Placebo Controlled, Group-comparison Study in Patients With Non-erosive Gastroesophageal Reflux Disease |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Gastroesophageal Reflux |
| Intervention type | Drug |
| Interventions | Famotidine |
| Enrollment | 480 |
| Start date | Sep 1, 2005 |
| First posted | Sep 2, 2005 |
| Last update posted | Nov 21, 2011 |
| Countries | Japan |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: